Ghimire Anand, Das Balabhadra Prasad, Mishra Subhash Chandra
Department of Otolaryngology and Head-Neck Surgery, B.P. Koirala Institute of Health Sciences, Dharan, Nepal.
Nepal Med Coll J. 2007 Mar;9(1):17-21.
This prospective randomized case controlled study was conducted to determine the efficacy of antihistamine (azelastine) nasal spray and compare it to steroid (beclomethasone) nasal spray on the symptoms of allergic rhinitis. Seventy five symptomatic patients of allergic rhinitis were included in this study. Diagnosis was made on the basis of history and physical examination. The patients were divided into three groups randomly. Group A was treated with Azelastine nasal spray, Group B was treated with Beclomethasone nasal spray and Group C was control group and only treated with steam inhalation. Efficacy of the treatment was assessed in the terms of Total Rhinitis Symptom Complex (TSC) scores and individual symptom score which was calculated on the basis of Okuda's grading system. Base line total symptom complex (TSC) scores were reduced in group A and group B by 84.0% after 4 week treatment whereas in group C it was reduced by only 38.0%. Decrease in mean score for sneezing was 95.0% in group A and group B whereas it was only 28.3% in group C. Similarly decrease in mean score for rhinorrhoea in azelastine group was 94.4% and in beclomethasone group was 95.3% in comparison to steam inhalation group where it was 25.0%. Only the beclomethasone reduced nasal stuffiness score significantly by 95.0%. No significant adverse effects of the drugs were observed. The present study establishes the relative efficacy and tolerability ofazelastine nasal spray as compared to beclomethasone nasal spray in symptomatic patients of allergic rhinitis.
本前瞻性随机病例对照研究旨在确定抗组胺药（氮卓斯汀）鼻喷雾剂的疗效，并将其与类固醇（倍氯米松）鼻喷雾剂对过敏性鼻炎症状的疗效进行比较。本研究纳入了75例有症状的过敏性鼻炎患者。根据病史和体格检查做出诊断。患者被随机分为三组。A组接受氮卓斯汀鼻喷雾剂治疗，B组接受倍氯米松鼻喷雾剂治疗，C组为对照组，仅接受蒸汽吸入治疗。根据总鼻炎症状复合体（TSC）评分和根据奥田分级系统计算的个体症状评分来评估治疗效果。治疗4周后，A组和B组的基线总症状复合体（TSC）评分降低了84.0%，而C组仅降低了38.0%。A组和B组打喷嚏平均评分的降低率为95.0%，而C组仅为28.3%。同样，与蒸汽吸入组（降低率为25.0%）相比，氮卓斯汀组鼻漏平均评分的降低率为94.4%，倍氯米松组为95.3%。只有倍氯米松使鼻阻塞评分显著降低了95.0%。未观察到药物的明显不良反应。本研究确定了在有症状的过敏性鼻炎患者中，与倍氯米松鼻喷雾剂相比，氮卓斯汀鼻喷雾剂的相对疗效和耐受性。
